Adalimumab,an approved monoclonal anti-TNFα antibody that is already usedin the clinic to treat IBD (see Materials and Methods for antibody purification), is used as a positive control and ourbivalent nanobody constructs show a similar binding capability tothis therapeutic. The gene discussed is TNF; the disease is inflammatory bowel disease.